95,094 total recalls in our database
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance.
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
CGMP Deviations: active pharmaceutical ingredient intermediates failed specifications.
Lack of Assurance of Sterility; some lots failed Antimicrobial Effectiveness Testing on stability
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance.
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance
Baptist Health Medical Towers Pharmacy and Infusion Services
Lack of Sterility Assurance.
Subpotent Drug
Compromised sterility due to breach of barrier
Compromised sterility due to breach of barrier
Potential for incomplete dissolution of the polyethylene glycol (PEG) component during the reconstitution of the product, which may affect the consistency of the hydrogel formation during use.
Potential for incomplete dissolution of the polyethylene glycol (PEG) component during the reconstitution of the product, which may affect the consistency of the hydrogel formation during use.
BBMI recently identified a potential for a tear in the outer blister packaging on a limited number of units. The tears have been identified in the blister package paper, where the unit label writing is located.
Abbott Laboratories
Interaction of Fulvestrant with the ARCHITECT Estradiol assay, leading to falsely elevated estradiol results in patients treated with Fulvestrant.